- Conditions
- Hypogonadism
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 200 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 70
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
- Interventions
- kisspeptin 112-121
- Drug
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadotropic Hypogonadism, Low Testosterone
- Interventions
- Naloxone
- Drug
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Hypogonadism, Hypogonadotropic Hypogonadism
- Interventions
- Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Miami Gardens, Florida
- Conditions
- Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
- Interventions
- Kisspeptin 112-121
- Drug
- Lead sponsor
- Stephanie B. Seminara, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Placebo, topical testosterone, Androxal
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 21 Years to 65 Years · Male only
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 18
- States / cities
- Garden Grove, California • Sacramento, California • San Diego, California + 11 more
- Conditions
- Obese Hypogonadotropic Hypogonadism
- Interventions
- Investigational new drug company code: BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 30 Years to 65 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
- Conditions
- Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
- Interventions
- gonadotropin releasing hormone (GnRH)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal 25 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Minneapolis, Minnesota
- Conditions
- Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
- Interventions
- Testosterone Gel (1%)
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 13 Years to 17 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal, AndroGel, Placebo
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
- Conditions
- Primary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 25 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- Kisspeptin 112-121, Naloxone, GnRH
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal 25 mg
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hypogonadism
- Interventions
- Nasobol®, Androderm® (Positive Control)
- Drug
- Lead sponsor
- Acerus Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- intranasal insulin, placebo (intranasal saline)
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Odessa, Texas
- Conditions
- Secondary Hypogonadism
- Interventions
- 25 mg Androxal, Testim 1%
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 21 Years to 60 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York • Purchase, New York
- Conditions
- Hypogonadism, Hypogonadotropic
- Interventions
- Clomiphene, Placebo
- Drug
- Lead sponsor
- Sandeep Singh Dhindsa, M.D., F.A.C.E
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypogonadotropic Hypogonadism, Type 2 Diabetes
- Interventions
- testosterone, clomiphene, placebo
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
- Interventions
- fispemifene, Placebo
- Drug · Other
- Lead sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • San Diego, California • Bradenton, Florida + 12 more
- Conditions
- Primary Amenorrhea With Hypogonadotropic Hypogonadism
- Interventions
- Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • San Francisco, California • Aurora, Colorado + 28 more
- Conditions
- Hypogonadotropic Hypogonadism, Amenorrhea, Kallmann's Syndrome
- Interventions
- GnRH, Pump
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more